Urine Biomarker Helps Classify Risk Level in Prostate Cancer
Urine-derived extracellular vesicle RNA provides diagnostic, prognostic information in prostate cancer.
Prostate Cancer News
PROSTATE ADVISOR
Prostate Cancer News
Routine mpMRI Use Leads to Earlier Treatment of Men on Prostate Cancer AS
Men on active surveillance for prostate cancer progress to treatment sooner if they undergo multiparametric MRI to identify clinically significant tumors.
Prostate Cancer Salvage Cryotherapy May Offer Durable Tumor Control
In a study, patients who underwent salvage cryotherapy for radiorecurrent prostate cancer had cancer-specific and metastasis-free survival rates of 81% and 78%, respectively, at 12 years.
Prostate Cancer Salvage Surgery, Ablation Offer Similar Outcomes
Radical prostatectomy and ablation for salvage treatment of radiorecurrent prostate cancer do not differ significant with regard to cancer-specific and metastasis-free survival, a study found.
Combination Biopsy Strategy May Identify More Prostate Cancers
A lesion visible on magnetic resonance imaging (MRI) identifies a heightened risk for clinically significant prostate cancer in men undergoing first-time prostate biopsy, and a combination of targeted and systematic biopsy may improve the chances of detecting cancer.
Active Surveillance for Intermediate-Risk PCa Increasing in US
Older men with favorable intermediate-risk prostate cancer treated in the West, Northwest, or Midwest were the biggest adopters of AS during the years 2010 and 2015.
Neoadjuvant Combo Reduces Volume of High-Risk Prostate Tumors
Abiraterone plus prednisone combined with leuprolide decreases tumor size compared with leuprolide alone in men with high-risk prostate cancer.
Adding Apalutamide to ADT Prolongs Survival in mCSPC
In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.
Prostate Cancer Detection Greater With Targeted Plus Systematic Biopsy
In a study, combining targeted and systematic biopsy detected 11% to 33% more prostate cancers than either method alone.
PET/CT Imaging for Recurrent PCa Detection More Accurate With PSMA
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
More Advanced PCa Diagnoses Followed USPSTF Screening Recommendations
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
Declining Use of Chemotherapy in the Last 2 Weeks of Life for Older Patients With Solid Tumor Cancers
During 2013, only 4.9% of older patients with the specified solid tumor cancers received chemotherapy within the last 14 days of life.
Location of Body Fat Linked to Advanced, Fatal Prostate Cancer
Specific fat deposits, body mass index (BMI), and waist circumference are associated with an increased risk for advanced and fatal prostate cancer.
Real-World Prostate Cancer Active Surveillance Less Than Ideal
In a study of prostate cancer patients from North Carolina, only 15% received monitoring as recommended by the NCCN.
Adding Enzalutamide to Testosterone Suppression Improves OS Compared With Active Control in Certain Prostate Cancers
Approximately 45% of men with newly diagnosed, hormone-sensitive prostate cancer enrolled in the ENZAMET trial also received early treatment with docetaxel.
Long-Term Results from GETUG-AFU 16: Further Evidence Supporting RT+HT as the Standard of Care After Radical Prostatectomy
Long-term follow-up of the randomized GETUG-AFU 16 study confirmed a significant improvement in metastatic-free survival when goserelin was added to salvage RT.
Darolutamide Delays Pain Progression, Deterioration in Urinary Symptoms in High-Risk Nonmetastatic CRPC
Investigators from the phase 3 ARAMIS trial reported a significant delay in PSA progression in patients with nonmetastatic CRPC receiving darolutamide.
Black PCa Patients Opt Less for Active Surveillance, Watchful Waiting
In 2015, black men were 16% less likely than nonblack men to choose active surveillance or watchful waiting for low-risk prostate cancer.
Prostate Cancer Recurrence Risk Higher With Extensive Positive Margins
In a study, just 12.1% of cases with focal positive surgical margins (PSM) experienced biochemical recurrence compared with 54.1% of those with extensive PSM.
SABR May Up Survival in Oligometastatic Cancers
New data from a phase 2 randomized trial suggest that stereotactic ablative radiotherapy to sites of metastases may prolong overall and progression-free survival.
Want to read more?
Please login or register first to view this content.
